CADL
Candel Therapeutics, Inc. NASDAQ Listed Jul 27, 2021$8.31
+4.00%
vs $7.99
Mkt Cap $456.2M
52w Low $4.35
75.9% of range
52w High $9.57
50d MA $7.52
200d MA $5.89
P/E (TTM)
-11.5x
EV/EBITDA
—
P/B
8.5x
Debt/Equity
0.0x
ROE
-73.5%
P/FCF
-11.3x
RSI (14)
50.10
ATR (14)
$0.61
Beta
-0.81
50d MA
$7.52
200d MA
$5.89
Avg Volume
2.3M
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CIK (SEC)
Phone
617 916 5445
117 Kendrick Street · Needham, MA 02494 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | BMO | -0.30 | -0.14 | +52.7% | 8.94 | +2.8% | -0.3% | -1.6% | -9.9% | -3.0% | +0.7% | — |
| May 13, 2026 | BMO | — | — | — | 8.72 | -0.6% | +2.5% | -0.3% | -1.6% | -9.9% | -3.0% | — |
| May 12, 2026 | BMO | — | — | — | 8.85 | +0.5% | -1.5% | +2.5% | -0.3% | -1.6% | -9.9% | — |
| Mar 12, 2026 | BMO | -0.24 | -0.54 | -125.0% | 4.98 | +1.2% | -6.2% | +6.9% | +3.6% | -2.5% | -2.6% | — |
| Nov 13, 2025 | BMO | -0.17 | -0.21 | -23.5% | 4.61 | -1.7% | +0.7% | +1.9% | -2.3% | -4.3% | +0.0% | — |
| Aug 14, 2025 | BMO | -0.17 | -0.09 | +47.1% | 6.04 | +0.8% | +0.8% | -2.1% | -6.7% | +0.0% | +4.1% | — |
| May 13, 2025 | BMO | -0.24 | 0.13 | +154.2% | 5.40 | +1.1% | -1.1% | -4.3% | +4.7% | +6.5% | +3.7% | — |
| Mar 13, 2025 | BMO | -0.23 | -0.40 | -73.9% | 7.94 | +0.3% | +10.2% | +0.9% | -0.1% | +0.9% | -7.3% | — |
| Nov 14, 2024 | BMO | — | -0.33 | — | 4.30 | +1.2% | -11.6% | +4.2% | +0.8% | -0.3% | +4.0% | — |
| Aug 13, 2024 | BMO | — | -0.74 | — | 5.84 | -0.7% | -9.9% | +2.3% | -2.0% | -0.4% | +0.0% | — |
| May 14, 2024 | BMO | — | -0.28 | — | 10.70 | +1.2% | +30.8% | -9.3% | -9.4% | +4.2% | +2.4% | — |
| Mar 28, 2024 | BMO | -0.16 | -0.38 | -137.5% | 1.58 | +8.9% | +10.8% | -3.4% | -0.6% | +281.0% | +3.8% | — |
| Nov 9, 2023 | BMO | -0.19 | -0.29 | -52.6% | 0.87 | +3.4% | +3.8% | +0.7% | +2.2% | +5.1% | +5.4% | — |
| Aug 10, 2023 | BMO | -0.23 | -0.33 | -43.5% | 1.06 | +1.9% | +8.5% | -0.0% | +0.9% | -3.4% | +0.9% | — |
| May 11, 2023 | BMO | -0.35 | -0.30 | +14.3% | 1.72 | -4.1% | -9.9% | +3.2% | -1.2% | -1.3% | +9.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | Citigroup | Maintains | Buy → Buy | — | $5.17 | $5.22 | +1.0% | -2.5% | -2.6% | +1.2% | +0.4% | -3.6% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.98 | $5.04 | +1.2% | -6.2% | +6.9% | +3.6% | -2.5% | -2.6% |
| Mar 13 | Citigroup | Maintains | Buy → Buy | — | $4.98 | $5.04 | +1.2% | -6.2% | +6.9% | +3.6% | -2.5% | -2.6% |
| Dec 8 | Stephens & Co. | Maintains | Overweight → Overweight | — | $5.33 | $5.42 | +1.7% | +2.3% | +3.9% | +2.5% | +11.6% | -1.9% |
| Nov 21 | Freedom Broker | Maintains | Buy → Buy | — | $4.42 | $4.44 | +0.5% | +2.9% | -0.4% | -1.3% | +3.4% | +3.2% |
| Nov 14 | Citigroup | Maintains | Buy → Buy | — | $4.61 | $4.53 | -1.7% | +0.7% | +1.9% | -2.3% | -4.3% | +0.0% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.54 | $5.59 | +0.9% | -2.5% | -5.6% | +8.6% | -2.3% | +2.8% |
| Sep 3 | BofA Securities | Downgrade | Buy → Neutral | — | $5.86 | $5.44 | -7.2% | -12.8% | -4.3% | +2.2% | +2.0% | -2.5% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.77 | $4.87 | +2.1% | +4.2% | +4.0% | -4.3% | -8.5% | +0.9% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.94 | $7.96 | +0.3% | +10.2% | +0.9% | -0.1% | +0.9% | -7.3% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.39 | $8.89 | +6.0% | +1.0% | +1.5% | +4.4% | -11.9% | -0.4% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.39 | $8.89 | +6.0% | +1.0% | +1.5% | +4.4% | -11.9% | -0.4% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.60 | $6.73 | +2.0% | -1.1% | +52.5% | -12.1% | -1.4% | +2.0% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.80 | $3.96 | +4.2% | +4.2% | +0.8% | -0.3% | +4.0% | +21.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.92 | +1.8% | +0.7% | +2.2% | +5.1% | +5.4% | -12.6% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.57 | $1.57 | +0.0% | +7.6% | -4.1% | -4.9% | -5.2% | -0.7% |
| May 15 | BMO Capital | Maintains | Outperform → Outperform | — | $1.55 | $1.56 | +0.6% | +3.2% | -1.2% | -1.3% | +9.6% | -8.1% |
| Mar 31 | Credit Suisse | Maintains | Outperform → Outperform | — | $1.38 | $1.40 | +1.3% | -2.4% | +4.4% | -0.7% | +1.4% | -2.1% |
| Dec 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $1.67 | $1.66 | -0.6% | -7.8% | +23.4% | +10.0% | +10.5% | -7.4% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.85 | +2.8% | +4.4% | +2.1% | -13.0% | -7.8% | +23.4% |
| Sep 2 | BMO Capital | Maintains | Outperform → Outperform | — | $3.50 | $3.36 | -4.0% | -6.6% | +2.8% | +4.2% | +12.6% | +3.6% |
| Mar 31 | BMO Capital | Maintains | Outperform → Outperform | — | $4.59 | $4.73 | +3.1% | +10.9% | +3.1% | -0.4% | -3.8% | -3.2% |
| Nov 19 | BMO Capital | Maintains | Outperform → Outperform | — | $10.70 | $10.99 | +2.7% | +1.6% | -9.8% | +2.4% | +2.8% | -5.2% |
| Aug 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.30 | $6.80 | +7.9% | +25.9% | -1.5% | -2.4% | +2.9% | +2.0% |
| Aug 23 | Jefferies | Maintains | Buy → Buy | — | $6.30 | $6.80 | +7.9% | +25.9% | -1.5% | -2.4% | +2.9% | +2.0% |
| Aug 23 | UBS | Maintains | Buy → Buy | — | $6.30 | $6.80 | +7.9% | +25.9% | -1.5% | -2.4% | +2.9% | +2.0% |
No insider trades available.
8-K · 5.02
!!! Very High
Candel Therapeutics, Inc. -- 8-K 5.02: Executive Change
Candel Therapeutics lost director Charles Schoch, signaling potential board transitions that investors should monitor for impact on governance and strategic direction.
Jun 16
8-K · 2.02
!! High
Candel Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
Unknown — 8-K Filing
Candel Therapeutics secured $130 million in debt financing, extending its cash runway to advance cancer immunotherapy development, but increasing financial obligations that could dilute shareholders if clinical trials fail.
Mar 12
8-K
Candel Therapeutics, Inc. -- 8-K Filing
Candel Therapeutics raised approximately $93.5 million through a public offering to fund commercial launch activities for its CAN-2409 therapy, with potential proceeds reaching $107.6 million if underwriters exercise their full option.
Feb 23
8-K · 8.01
!! High
Candel Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
I need more details from the filing summary to provide meaningful analysis. The provided text appears incomplete and doesn't contain substantive information about Candel Therapeutics' material event or announcement.
Could you provide the actual content describing what the material event or announcement was?
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 10,987,017 | $54M | Added | Mar 2026 |
| 2 | Rtw Investments, Lp | 6,422,018 | $31M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,462,757 | $12M | New | Mar 2026 |
| 4 | Millennium Management | 1,060,086 | $5M | New | Mar 2026 |
| 5 | Heights Capital Management, Inc | 775,000 | $4M | New | Mar 2026 |
| 6 | Sands Capital Alternatives, Llc | 405,837 | $2M | — | Mar 2026 |
| 7 | Northern Trust Corp | 323,154 | $2M | Added | Mar 2026 |
| 8 | Morgan Stanley | 268,062 | $2M | Added | Dec 2025 |
| 9 | Vanguard Portfolio Management Llc | 268,249 | $1M | New | Mar 2026 |
| 10 | Tanager Wealth Management Llp | 198,175 | $971K | — | Mar 2026 |
| 11 | Janus Henderson Group Plc | 171,978 | $845K | New | Mar 2026 |
| 12 | Woodline Partners Lp | 156,700 | $768K | New | Mar 2026 |
| 13 | Ubs Group Ag | 149,855 | $734K | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 136,266 | $668K | Added | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 112,973 | $554K | Reduced | Mar 2026 |
| 16 | Point72 Asset Management | 107,211 | $525K | New | Mar 2026 |
| 17 | Stonepine Capital Management, Llc | 102,500 | $502K | New | Mar 2026 |
| 18 | Commonwealth Equity Services, Llc | 82,346 | $465K | — | Dec 2025 |
| 19 | Two Sigma Investments, Lp | 93,500 | $458K | Reduced | Mar 2026 |
| 20 | Nuveen, Llc | 93,158 | $456K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$456.2M
Enterprise Value
$321.8M
P/E (TTM)
-11.54x
Forward P/E
—
PEG Ratio
0.13x
P/B
8.48x
P/S
—
P/FCF
-11.31x
EV/EBITDA
—
Shares Out
53.0M
Financials (TTM)
Revenue
$0
Net Income
-$38.2M
EBITDA
-$47.4M
Free Cash Flow
-$38.9M
Op Cash Flow
-$38.3M
EPS Basic
$-0.72
EPS Diluted
$-0.72
EPS Forward
$-1.26
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$125.2M
Total Liab.
$73.3M
Total Equity
$51.9M
Cash
$119.7M
LT Debt
$1.5M
Book Value/Sh
$0.98
Debt/Equity
0.04x
Current Ratio
13.31
Quick Ratio
13.31
Returns & Growth
ROE
-73.5%
ROA
-30.5%
ROIC
-41.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+58.6%
Price Returns
2W
-6.8%
1M
+34.3%
3M
+58.1%
6M
+74.0%
12M
+52.3%
Technicals
52W High
$9.57
52W Low
$4.35
50d MA
$7.52
200d MA
$5.89
RSI (14)
50.10
ATR (14)
$0.61
Beta
-0.81
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.00
High
$15.00
Low
$15.00
Median
$15.00
Data updated apr 24, 2026 11:38pm
· Source: financialmodelingprep.com